Relates to prescription drug formulary coverage for interchangeable biologics and biosimilars.
Impact
If enacted, this bill may significantly alter how insurers categorize and provide coverage for biologics and biosimilars. The changes aim to prevent insurers from imposing excessive barriers, such as requiring patients to switch to less expensive alternatives before approving coverage for prescribed biologic medications. By supporting interchangeable medications in formulary, the bill seeks to enhance patient access to potentially more affordable treatment options, thereby addressing concerns over escalating healthcare costs for patients relying on these medications for chronic conditions.
Summary
Bill S03485 aims to amend the insurance law regarding prescription drug formulary coverage specifically for interchangeable biologics and biosimilars. This legislation acknowledges the increasing importance of biologics in treatment regimens while fostering the inclusion of biosimilars and interchangeable products in health insurance coverage. The proposed amendments seek to streamline the processes through which insurers manage their formularies, ensuring that patients have easier access to these drugs without undue burden from stringent insurance requirements.
Contention
Despite its aim to benefit patients, there could be notable points of contention surrounding Bill S03485. Insurance companies might argue that such changes could increase their operational costs as they would have to accommodate a broader range of drug options within their plans. Additionally, there may be dissent regarding the implications for patient safety and the integrity of prescribed treatment protocols, as some stakeholders believe that mandatory coverage of biosimilars could compromise individual treatment strategies that are specifically tailored to patient needs.
Requires health plan coverage to include generic drugs and biosimilars where the wholesale acquisition cost of such generic drugs or biosimilars is lower than the brand drug's wholesale acquisition cost.
Authorizes insurance policies which provide coverage for prescription drugs where cost-sharing obligations are determined by category of prescription drugs to offer a program to insureds that utilizes rebates or discounts to lower an insured's cost-sharing for prescription drugs if the insured's cost-sharing under such program would be more favorable than the cost-sharing that would otherwise be applicable to the prescription drug.
Authorizes insurance policies which provide coverage for prescription drugs where cost-sharing obligations are determined by category of prescription drugs to offer a program to insureds that utilizes rebates or discounts to lower an insured's cost-sharing for prescription drugs if the insured's cost-sharing under such program would be more favorable than the cost-sharing that would otherwise be applicable to the prescription drug.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a sixty-day (60) supply may be dispensed at any one time.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a ninety-day (90) supply may be dispensed at any one time.